A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."
Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.
Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”
Starboard Value CEO Jeffrey C. Smith and former Bayer consumer health chief Erica Mann among three added to board at Kenvue, which increasing the number of seats temporarily from 11 to 14 until trimming it to 13 at its 2025 annual shareholders meeting on a date yet to be set.
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.
Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.
CEO says firm’s “three clear imperatives” to drive cash and “total shareholder return” comprise its “three S” plan. Perrigo’s net sales for the quarter down 1.6% to $1.14bn and for the year down 6.1% to $4.37bn.
Full-year revenues up 14% to $732m and Q4 up 5% to $186m. Communications VP Dan Dischner says results came from “resilience of our portfolio, driven by contributions from key products such as Primatene Mist and the integration of Baqsimi into our expanding diabetes franchise.”
Almost two thirds (62%) of respondents to an online survey said they would rather buy non-prescription medicines in a local pharmacy than via a mail-order pharmacy, Pharma Deutschland reports.
Start-ups and individuals working on innovative consumer health concepts, in categories such as pain relief and dietary supplements, have the opportunity to access Haleon's resources and expertise to make their ideas a reality.
Voltarol One A Day Muscle Pain Relief Medicated Plaster provides up to 24 hours relief from pain and inflammation, according to manufacturer Haleon.
HBW Insight speaks to AdverCheck managing director James Walmsley about the rise of direct-to-consumer prescription drugs marketing in the UK, and its impact on the consumer healthcare industry.
Analysts hold back on predicting new heights for B+L until full split from parent firm. It reported Q4 revenue up 9% to $1.28bn and full-year revenue up 16% to $4.79bn.
The Swedish firm is plotting the path towards launching its ColdZyme virus-blocking spray in China and Japan, while efforts are also underway to find a partner for the North American market.
Energy, immunity and women's health supplements were in particular demand in 2024, according to French self-care industry association NèreS.